ADC Therapeutics (ADCT) Competitors

$3.42 -0.07 (-1.87%)

As of 03:31 PM Eastern

ADCT vs. HRMY, TRVI, VCEL, ANIP, and INBX

Should you buy ADC Therapeutics stock or one of its competitors? MarketBeat compares ADC Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ADC Therapeutics include Harmony Biosciences (HRMY), Trevi Therapeutics (TRVI), Vericel (VCEL), ANI Pharmaceuticals (ANIP), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry.

How does ADC Therapeutics compare to Harmony Biosciences?

ADC Therapeutics (NYSE:ADCT) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

ADC Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	5.28	-$142.62M	-$1.05	N/A
Harmony Biosciences	$868.45M	2.05	$158.69M	$2.48	12.42

Harmony Biosciences has a net margin of 16.20% compared to ADC Therapeutics' net margin of -173.02%. Harmony Biosciences' return on equity of 17.19% beat ADC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Harmony Biosciences	16.20%	17.19%	11.99%

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Harmony Biosciences had 11 more articles in the media than ADC Therapeutics. MarketBeat recorded 12 mentions for Harmony Biosciences and 1 mentions for ADC Therapeutics. Harmony Biosciences' average media sentiment score of 0.84 beat ADC Therapeutics' score of -0.49 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harmony Biosciences	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADC Therapeutics presently has a consensus price target of $8.00, indicating a potential upside of 137.04%. Harmony Biosciences has a consensus price target of $40.89, indicating a potential upside of 32.78%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe ADC Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Summary

Harmony Biosciences beats ADC Therapeutics on 12 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and ADC Therapeutics (NYSE:ADCT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Trevi Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
ADC Therapeutics	-173.02%	N/A	-44.70%

Trevi Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the broader market.

In the previous week, Trevi Therapeutics had 15 more articles in the media than ADC Therapeutics. MarketBeat recorded 16 mentions for Trevi Therapeutics and 1 mentions for ADC Therapeutics. Trevi Therapeutics' average media sentiment score of 0.69 beat ADC Therapeutics' score of -0.49 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Trevi Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
ADC Therapeutics	$81.36M	5.28	-$142.62M	-$1.05	N/A

Trevi Therapeutics currently has a consensus price target of $22.90, indicating a potential upside of 52.51%. ADC Therapeutics has a consensus price target of $8.00, indicating a potential upside of 137.04%. Given ADC Therapeutics' higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Trevi Therapeutics beats ADC Therapeutics on 11 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Vericel?

Vericel (NASDAQ:VCEL) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Vericel has a net margin of 7.35% compared to ADC Therapeutics' net margin of -173.02%. Vericel's return on equity of 6.41% beat ADC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
ADC Therapeutics	-173.02%	N/A	-44.70%

Vericel has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the broader market.

In the previous week, Vericel had 20 more articles in the media than ADC Therapeutics. MarketBeat recorded 21 mentions for Vericel and 1 mentions for ADC Therapeutics. Vericel's average media sentiment score of 0.91 beat ADC Therapeutics' score of -0.49 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

41.1% of ADC Therapeutics shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vericel has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	6.21	$16.52M	$0.42	79.95
ADC Therapeutics	$81.36M	5.28	-$142.62M	-$1.05	N/A

Vericel currently has a consensus price target of $55.40, indicating a potential upside of 64.99%. ADC Therapeutics has a consensus price target of $8.00, indicating a potential upside of 137.04%. Given ADC Therapeutics' higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Vericel beats ADC Therapeutics on 12 of the 15 factors compared between the two stocks.

How does ADC Therapeutics compare to ANI Pharmaceuticals?

ADC Therapeutics (NYSE:ADCT) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ADC Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 137.04%. ANI Pharmaceuticals has a consensus price target of $107.33, indicating a potential upside of 35.11%. Given ADC Therapeutics' higher probable upside, equities analysts clearly believe ADC Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88

ADC Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

ANI Pharmaceuticals has a net margin of 9.98% compared to ADC Therapeutics' net margin of -173.02%. ANI Pharmaceuticals' return on equity of 27.51% beat ADC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

In the previous week, ANI Pharmaceuticals had 26 more articles in the media than ADC Therapeutics. MarketBeat recorded 27 mentions for ANI Pharmaceuticals and 1 mentions for ADC Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.30 beat ADC Therapeutics' score of -0.49 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	8 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ANI Pharmaceuticals has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	5.28	-$142.62M	-$1.05	N/A
ANI Pharmaceuticals	$883.37M	2.02	$78.34M	$3.95	20.11

Summary

ANI Pharmaceuticals beats ADC Therapeutics on 14 of the 17 factors compared between the two stocks.

How does ADC Therapeutics compare to Inhibrx Biosciences?

ADC Therapeutics (NYSE:ADCT) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Inhibrx Biosciences has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Inhibrx Biosciences	N/A	-269.56%	-71.94%

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ADC Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.88, suggesting that its share price is 288% more volatile than the broader market.

Inhibrx Biosciences has lower revenue, but higher earnings than ADC Therapeutics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	5.28	-$142.62M	-$1.05	N/A
Inhibrx Biosciences	$1.30M	1,328.17	-$140.05M	-$9.04	N/A

In the previous week, Inhibrx Biosciences had 8 more articles in the media than ADC Therapeutics. MarketBeat recorded 9 mentions for Inhibrx Biosciences and 1 mentions for ADC Therapeutics. Inhibrx Biosciences' average media sentiment score of 0.23 beat ADC Therapeutics' score of -0.49 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADC Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 137.04%. Inhibrx Biosciences has a consensus price target of $150.00, indicating a potential upside of 26.92%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe ADC Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Inhibrx Biosciences beats ADC Therapeutics on 9 of the 17 factors compared between the two stocks.

Get ADC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADCT vs. The Competition

Export

Metric	ADC Therapeutics	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$433.08M	$3.40B	$6.29B	$22.99B
Dividend Yield	N/A	2.31%	2.79%	4.07%
P/E Ratio	-3.24	18.81	20.91	28.42
Price / Sales	5.28	284.65	548.78	24.19
Price / Cash	N/A	122.51	42.94	25.11
Price / Book	-1.99	6.78	9.87	4.75
Net Income	-$142.62M	$24.11M	$3.55B	$1.06B
7 Day Performance	-10.36%	0.22%	-0.24%	-0.67%
1 Month Performance	-12.56%	1.08%	1.44%	1.82%
1 Year Performance	88.02%	78.09%	41.01%	25.05%

ADC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADCT ADC Therapeutics	2.1417 of 5 stars	$3.42 -1.9%	$8.00 +134.3%	+163.3%	$434.35M	$81.36M	N/A	310
HRMY Harmony Biosciences	4.8222 of 5 stars	$32.81 +0.7%	$42.67 +30.0%	-10.3%	$1.90B	$868.45M	12.08	200	Earnings Report
TRVI Trevi Therapeutics	3.3911 of 5 stars	$14.58 +1.4%	$21.60 +48.2%	+136.7%	$1.88B	N/A	N/A	20
VCEL Vericel	3.8498 of 5 stars	$37.02 +1.4%	$55.40 +49.7%	-24.7%	$1.88B	$276.26M	119.13	300	Earnings Report Analyst Downgrade Analyst Revision
ANIP ANI Pharmaceuticals	3.7701 of 5 stars	$83.44 +1.4%	$107.33 +28.6%	+30.5%	$1.87B	$883.37M	24.79	600	Trending News Earnings Report Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ADCT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADC Therapeutics (ADCT) Competitors

ADCT vs. HRMY, TRVI, VCEL, ANIP, and INBX

How does ADC Therapeutics compare to Harmony Biosciences?

Summary

How does ADC Therapeutics compare to Trevi Therapeutics?

Summary

How does ADC Therapeutics compare to Vericel?

Summary

How does ADC Therapeutics compare to ANI Pharmaceuticals?

Summary

How does ADC Therapeutics compare to Inhibrx Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADC Therapeutics (ADCT) Competitors

ADCT vs. HRMY, TRVI, VCEL, ANIP, and INBX

How does ADC Therapeutics compare to Harmony Biosciences?

Which has more volatility and risk, ADCT or HRMY?

Which has better valuation & earnings, ADCT or HRMY?

Is ADCT or HRMY more profitable?

Do insiders and institutionals believe in ADCT or HRMY?

Does the media prefer ADCT or HRMY?

Do analysts prefer ADCT or HRMY?

Summary

How does ADC Therapeutics compare to Trevi Therapeutics?

Is TRVI or ADCT more profitable?

Which has more volatility and risk, TRVI or ADCT?

Does the media refer more to TRVI or ADCT?

Do institutionals and insiders have more ownership in TRVI or ADCT?

Which has stronger earnings and valuation, TRVI or ADCT?

Do analysts recommend TRVI or ADCT?

Summary

How does ADC Therapeutics compare to Vericel?

Is VCEL or ADCT more profitable?

Which has more volatility and risk, VCEL or ADCT?

Does the media refer more to VCEL or ADCT?

Do institutionals and insiders have more ownership in VCEL or ADCT?

Which has stronger earnings and valuation, VCEL or ADCT?

Do analysts recommend VCEL or ADCT?

Summary

How does ADC Therapeutics compare to ANI Pharmaceuticals?

Do institutionals and insiders have more ownership in ADCT or ANIP?

Do analysts recommend ADCT or ANIP?

Which has more risk and volatility, ADCT or ANIP?

Is ADCT or ANIP more profitable?

Does the media refer more to ADCT or ANIP?

Which has preferable earnings & valuation, ADCT or ANIP?

Summary

How does ADC Therapeutics compare to Inhibrx Biosciences?

Is ADCT or INBX more profitable?

Do institutionals and insiders have more ownership in ADCT or INBX?

Which has more risk and volatility, ADCT or INBX?

Which has preferable earnings & valuation, ADCT or INBX?

Does the media refer more to ADCT or INBX?

Do analysts recommend ADCT or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools